Skip to main content
Figure 5 | BMC Pulmonary Medicine

Figure 5

From: Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study

Figure 5

Change from baseline in SGRQ total score at 24 weeks (ITT population). Data are presented as least squares means (SE). FDC, aclidinium/formoterol fixed-dose combination; ITT, intent-to-treat; MCID, minimum clinically important difference; SE, standard error; SGRQ, St George’s Respiratory Questionnaire.

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us